Portfoliotracker

SAB Biotherapeutics, Inc.

SABS · NASDAQCM · Healthcare Biotechnology 9/100 E

3,000 $
▲ +0,040 (+1,35 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:35
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score9 / 100 Market cap280 mil. $ P/E– Forward P/E-3,2 P/S– P/B1,3 EV/EBITDA– Dividend yield– FCF yield– EPS-1,37 $ Net margin0,0 % Return on equity-42,8 % Beta0,75 Debt / equity0,02
52-week range 2,44 to 5,15
3-month average volume0,6 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Website
sab.bio
Employees
86
Country
United States
Fiscal year end
31. 12.
Data since
9. 2. 2021

Explore further

Similar companies ABOSSRZN

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account